[go: up one dir, main page]

WO2025169152A1 - Conjugués protéine végétale-polyphénol de thé vert utilisés comme émulsifiants - Google Patents

Conjugués protéine végétale-polyphénol de thé vert utilisés comme émulsifiants

Info

Publication number
WO2025169152A1
WO2025169152A1 PCT/IB2025/051338 IB2025051338W WO2025169152A1 WO 2025169152 A1 WO2025169152 A1 WO 2025169152A1 IB 2025051338 W IB2025051338 W IB 2025051338W WO 2025169152 A1 WO2025169152 A1 WO 2025169152A1
Authority
WO
WIPO (PCT)
Prior art keywords
nano
emulsion
dmt
psychedelic
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2025/051338
Other languages
English (en)
Inventor
William HOSIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huxley Health Inc
Original Assignee
Huxley Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huxley Health Inc filed Critical Huxley Health Inc
Publication of WO2025169152A1 publication Critical patent/WO2025169152A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Definitions

  • compositions are known to modulate activity at the serotonin receptors.
  • a number of pharmaceuticals (antidepressants, serotonin reuptake inhibitors, selective serotonin reuptake inhibitors, etc.) have become available. Almost all these pharmaceuticals target neurotransmitters, e.g., serotonergic receptors, adrenergic receptors, dopaminergic receptors, etc., and in different ways. All ten of the leading pharmaceutical products for treating mood disorders (such as depression, obsessive compulsive disorder, and/or anxiety disorders) target serotonin pathways.
  • mood disorders such as depression, obsessive compulsive disorder, and/or anxiety disorders
  • psychedelic and or psychotomimetic symptoms should be paired with ancillary therapies, which include a particular physical setting, in addition to pre, during, and post drug administration counseling and/or psychotherapy (talk therapy) to achieve therapeutic efficacy for certain psychiatric disorders.
  • ancillary therapies which include a particular physical setting, in addition to pre, during, and post drug administration counseling and/or psychotherapy (talk therapy) to achieve therapeutic efficacy for certain psychiatric disorders.
  • ancillary therapies which include a particular physical setting, in addition to pre, during, and post drug administration counseling and/or psychotherapy (talk therapy) to achieve therapeutic efficacy for certain psychiatric disorders.
  • ancillary therapies which include a particular physical setting, in addition to pre, during, and post drug administration counseling and/or psychotherapy (talk therapy) to achieve therapeutic efficacy for certain psychiatric disorders.
  • the psychedelic experience (which can include alterations in consciousness, emotion, and cognition, and positive and negative psychotomimetic symptoms)
  • a widely utilized approach to achieve sustained solubilization and overcome poor fasted state bioavailability of lipophilic drugs is to utilize solutions in lipid vehicles containing surfactants that constitute.
  • Protein-polyphenol conjugate stabilized nanoemulsions produce opaque, brown emulsions with lipid droplet sizes of ⁇ 200 nm.
  • PPCSNEs can be manufactured using high- energy micro fluidics.
  • flavonoids The most abundant flavonoids in the typical diet are flavanols (catechins plus proanthocyanidins), anthocyanins and their oxidation products.
  • the main polyphenol dietary sources are fruit and beverages (fruit juice, wine, tea, coffee, chocolate and beer) and, to a lesser extent, vegetables, dry legumes and cereals.
  • the total amounts of pre-synthesized composite species made up of a biocompatible protein and polyphenolic species surfactant and optional co-surfactant, combined, are generally within a range from about 1-50 preferably an amount within the range of 10-40 wt%, and more preferably an amount within the range from about 15-35 wt% of the total PPCSNEs weight,
  • inflammatory disorders refers to one or more disorders selected from the following inflammatory disorders, of atherosclerosis, asthma, rheumatoid arthritis, psoriasis, type II diabetes, irritable bowel syndrome, Crohn's disease, septicemia, depression, schizophrenia, multiple sclerosis, conjunctivitis, Alzheimer's disease, chronic obstructive pulmonary disease, neuro-inflammation, metabolic syndrome, impaired glucose tolerance, non-alcoholic fatly liver disease (NAFLD), (NAFL) and their complications, non-alcoholic steatohepatitis (NASH) and conjunctivitis.
  • the general method of treatment comprises administering to a human or mammal subject in need thereof a therapeutically effective amount of an acceptable psychedelic analogue in one or more pharmaceutically acceptable carriers or excipients.
  • psychedelic state is an altered state of consciousness experienced by a person, which may include intensified sensory perception, perceptual distortion or hallucinations, and/or feelings of euphoria or despair.
  • Psychedelic states have been described as resulting from psychedelic drugs such as DMT (dimethyltryptamine), LSD, mescaline or psilocybin.
  • Other known psychedelic drags include but are not limited to, 4-hydroxy analogs of .N-methyl-N-isopropyltryptamine (MiPT) and WA’-diisopropyhryptamine (DiPT).
  • compositions which comprise a therapeutically effective amount of one or more of the compositions described herein, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents, and optionally, one or more additional therapeutic agents. While it is possible for a composition described herein to be administered alone, it is preferable to administer the composition as a pharmaceutical composition.
  • pharmaceutical composition means a composition comprising a composition of the invention in combination with at least one additional pharmaceutically acceptable carrier.
  • nasally including administration to the nasal membranes, such as by inhalation spray; or rectally such as in the form of suppositories.
  • the dosage of the drug or prodrug for a therapy session when used for the indicated effects, will range between about 0.001 to about 500 mg per dose, preferably between about 0.01 to about 200 mg per dose, and most preferably between about 0.1 to about 50 mg per dose, such as 10, 20, 30, 40, 50, 100 or 200 mg.
  • the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion.
  • Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet, dry, or melt granulated, melt congealed, or extruded before tableting.
  • the final formulation may include one or more layers and may be coated or uncoated; or encapsulated.
  • a typical capsule for oral administration contains at least one of the formulations of the present invention (e.g. 25 mg), lactose (e.g. 75 mg), and magnesium stearate (e.g. 15 mg).
  • the mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.
  • Liquid formulations may also be administered in the form of a nasal spray that provides direct contact with mucosal membranes in relatively close proximity to the blood- brain barrier.
  • a preferred mechanism for delivery is a nasal spray that delivers a metered amount with each pump, so the volume of sprayed nano-emulsion is substantially consistent from dose to dose.
  • Compositions of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol containing polymers, in order to improve their solubility, dissolution rate, taste masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
  • compositions of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art, Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compositions of the invention employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a composition of the invention will be an amount of the composition which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
  • a "therapeutically effective amount” refers to that amount of a composition being administered which will relieve to some extent one or more of the symptoms of the disorder being treated.
  • a therapeutically effective amount refers to that amount which has the effect of reducing the severity of depression.
  • Depression severity may be assessed using well-known structured assessment tools such as Structured Clinical Interview for DSM-5 (SCID-5) and the GRID-Hamilton Depression Rating Scale (GRIDHAMD).
  • a therapeutically effective amount may be less than that required for a psychedelic state.
  • an effective dosage can be administered in one or more administrations.
  • an effective dosage of drug, composition, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly.
  • an effective dosage of drug, composition or pharmaceutical composition may or may not be achieved in conjunction with another therapy, drug, composition, or pharmaceutical composition.
  • Treatment with the drug/prodrug compositions of the present invention may substantially alleviate clinical or subclinical depression and may avoid relapse, particularly if used in combination with psychotherapy for the treatment of depression. It is known that administration of an effective dose of psilocybin produced rapid and large reductions in depressive symptoms, and many subjects achieve remission through a four-week follow up (Davis et. al .). Without restriction to a theory, it is believed that the psychedelic state is associated with the beneficial effects, ho wever, some compositions which are 5HT 2A R agonists may provide the desired therapeutic effect without the psychedelic state.
  • One aspect of the invention comprises prodrugs of those 5HT 2A R agonists which do provide a beneficial therapeutic state
  • the invention may comprise a method of treating mental disorders comprising administering to a subject in need thereof a therapeutically effective amount of a composition of the present invention.
  • a method of treating depression by administering to a subject in need thereof therapeutically effective amount of a composition of the present invention.
  • the depression effects may be drug-resistant depression or major depressive disorder.
  • the physician may prefer to divide the therapeutic dose and thereby reduce the initial onset of psychoactivity before applying the full complement of the dosage to achieve the full effect.
  • compositions were initially prepared by synthesizing the hemp protein - polyphenol conjugate through covalent (HP-GTP cov ), and non- covalent ( HP-GTP noncov ) linkage.
  • nano-emulsions were stress tested under different chemical and physical environments mimicking commercial production and storage conditions to evaluate its longterm stability.
  • the average droplet sizes, polydispersity index, and zeta potentials for onr nanoemulsions were promising under this stress testing.
  • Biological assays were used to evaluate the effect of our nano-emulsions on cells. Cytotoxicity was evaluated using normal and cancer cells for both formulations A and B. Cellular uptake studies confirmed that formulations A and B both exhibited greater uptake of 5-MeO-DMT by human cells without attendant toxicity.
  • the PPCSNEs oil-in-water (O/W) NEs of 5-MeO-DMT stabilized by the HP - GTP conjugates were prepared by a method previously described by Banerjee et al., “Synthesis, characterization and stress-testing of a robust quillaja saponin stabilized oil-in-water phytocannabinoid nanoemulsion” Journal of Cannabis Research 2021, 3, 43, with some modifications, the disclosure of which is hereby incorporated by reference. A round-bottom flask equipped with a stir bar was charged with 5-MeO-DMT and a requisite amount of hemp oil under an N 2 atmosphere.
  • the two phases were then combined and mixed using a rotor-stator mixer (IKA T18 digital) at 10,000 rpm for 3 cycles of 60 sec on, and 60 sec off to avoid excessive internal heating.
  • the resulting coarse emulsion was then placed in the high-pressure homogenizer (Nano DeBee, BEE International, USA) and homogenized at a pressure of 20,000 - 25,000 psi in five sequential cycles using the Z8 nozzle with an aperture size of 0.20 mm.
  • the resulting brown solutions of the NEs were then kept in sealed transparent vials at ⁇ 4 °C for long-term storage.
  • the 5-MeO-DMT NE formed from HP - GTP noncov is referred to as the non-covalent conjugate emulsion (NCCE), while that formed from HP - GTP cov is referred to as the covalent conjugate emulsion (CCE).
  • NCE non-covalent conjugate emulsion
  • CCE covalent conjugate emulsion
  • DLS dynamic light scattering
  • This technique generated Z-average diameters of the dispersed lipid phase droplets (dz), as well as the polydispersity index (PDI). Diluted samples (50- to 100-fold dilutions) were used to avoid multiple scattering. The measurements were conducted with the Zetasizer (Nano Z S, Malvern Instruments Ltd., UK). The Z-average diameters of the dispersed phase droplets was calculated from the autocorrelation function of the intensity of light scattered from the particles. Phase-separated nano-emulsions were re-mixed by shaking prior to dilution for DLS measurements.
  • both formulations A and B form emulsions with average droplet sizes of about 200 nm, a narrow range of nanoparticle sizes, and good loading levels that can be further increased.
  • this basic formulation will produce nano-emulsions having an average droplet size within the range from about 10 nm to less than 300 nm, preferably within the range of about 20-250 nm, and even more preferably within the range of about 30- 200 mn.
  • the aqueous phase was prepared by adding the requisite amount of HP - GTP noncov/cov surfactant along -with any secondary surfactant (e.g. Tween 80) to HPLC grade water. This aqueous phase was then centrifuged at 2500 rpm for 5 minutes (VWR® Centrifuge with 15 mL rotor, 76019-132) and the supernatant was retained; this removed any insoluble protein aggregates. The two phases were then combined and mixed using a rotor-stator mixer (IKA T 18 digital) at 10,000 rpm for 3 cycles of 60 sec on, and 60 sec off to avoid excessive internal heating.
  • a rotor-stator mixer IKA T 18 digital
  • Flash heating 1 g of the optimized nano-emulsion was placed in a preheated water bath and the internal temperature of the nano-emulsion was maintained at 80 °C for 1 minute.
  • This protocol is a more extreme version of the high-temperature short-time (HTST) pasteurization process (typically, 71.5 °C. for 15 s) that fruit juices and milk beverages are subjected to in the industry.
  • the nano-emulsion was then allowed to cool to room temperature, and a part of it was diluted for DLS study. The rest was retained for HPLC analysis
  • Freeze-thaw cycle 1 g of the optimized nanoemulsion was placed in a freezer at a temperature of -20 °C for 1 hour. The nano-emulsion was then removed from the freezer and allowed to revert to room temperature. A part of the thawed nano-emulsion was diluted for DLS study, and the rest was retained for HPLC analysis.
  • the gradient run was as follows: 0 - 3.68 (3% B), 3.68 - 6.35 (5% B), 6.35 - 7.68 (15% B), 7.68 - 12.60 (15% B), 13.60 - 15.01 (100% B), 15.01 - 16.50 (3% B) and 16.50 - 18.00 (3% B).
  • Mobile phase solvents were of HPLC grade and fdtered with 0.20 um filters before analysis.
  • Standard dilutions of 5-MeO-DMT from 0.119 mg mL -1 to 0.001 mg mL -1 were run alongside sample extracts and data generated from standard dilutions acquisition was used to plot a calibration curve for calculating the concentration of 5-MeO-DMT in emulsion samples.
  • the human breast cancer cell line MDA-MB-231 was obtained from ATTC and were grown in Dulbecco’s modified Eagle's medium (DMEM, Sigma- Aldrich), 10% FBS (Sigma- Aldrich), and 1% penicillin/streptomycin (Sigma-Aldrich) at 37 °C in a 5% CO 2 atmosphere with 95% humidity.
  • the human glioblastoma cell U87 was purchased from ATTC and cultured in Minimal Essential Medium+ Earl’s Balanced Salts (MEM/EBSS, Hyclone, Logan, UT, USA), 10% FBS (Sigma-Aldrich), and 1% penicillin/streptomycin (Sigma- Aldrich) at 37 °C at 5% CO2 and 95% humidity .
  • the culture media was then replaced with this fresh media containing the respective NEs, and the cells were incubated for an additional 24 hours (37 °C, 5% CO 2 , 95% humidity).
  • the media was then removed by aspiration, and the cells were gently washed with PBS to remove any remaining NEs. Subsequently, the cells were harvested and washed with phosphate-buffered saline (PBS) containing EDTA.
  • PBS phosphate-buffered saline
  • the cells were suspended in PBS containing 2 mM ethylenediaminetetraacetic acid (EDTA). and a 500 ⁇ L single-cell suspension was analyzed using the BD LSRFortessaTM X-20 flow cytometer (Becton Dickinson).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé d'assemblage de nanoémulsions stabilisées de conjugués protéine-polyphénol (PPCSNE) par un procédé qui comprend les étapes consistant à : (a) combiner (i) un premier tensioactif constitué d'une espèce composite pré-synthétisée composée d'une protéine biocompatible et d'espèces polyphénoliques, (ii) une quantité thérapeutique d'un ou de plusieurs principes actifs psychédéliques, (iii) une huile de triglycéride et éventuellement (iv) un co-tensioactif dans un récipient, (b) procéder à un mélange à cisaillement élevé desdits ingrédients dans un récipient pour former un produit d'émulsion grossière et (c) faire passer l'émulsion grossière à travers un dispositif microfluidique pour produire une nanoémulsion de conjugués protéine-polyphénol contenant un agent psychédélique.
PCT/IB2025/051338 2024-02-07 2025-02-07 Conjugués protéine végétale-polyphénol de thé vert utilisés comme émulsifiants Pending WO2025169152A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463550914P 2024-02-07 2024-02-07
US63/550,914 2024-02-07

Publications (1)

Publication Number Publication Date
WO2025169152A1 true WO2025169152A1 (fr) 2025-08-14

Family

ID=96699317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2025/051338 Pending WO2025169152A1 (fr) 2024-02-07 2025-02-07 Conjugués protéine végétale-polyphénol de thé vert utilisés comme émulsifiants

Country Status (1)

Country Link
WO (1) WO2025169152A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020018512A1 (fr) * 2018-07-19 2020-01-23 Nanogen Lab, Inc. Substances hydrophobes en nanoémulsion
US20240226005A1 (en) * 2023-01-06 2024-07-11 Huxley Health Inc. Nano- and micro-formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020018512A1 (fr) * 2018-07-19 2020-01-23 Nanogen Lab, Inc. Substances hydrophobes en nanoémulsion
US20240226005A1 (en) * 2023-01-06 2024-07-11 Huxley Health Inc. Nano- and micro-formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOSIE WILLIAM CHARLES, EGBUTA MARY AUGUSTINA, RAZMKHAH KASRA, BOLANDI BEHZAD, DEHVARI KHALILALRAHMAN, HOMON ANTON, KAPPADAKUNNEL A: "Hemp proteins conjugated with green tea polyphenol extract form de novo plant-sourced emulsifiers suitable for nanodelivery systems bearing lipophilic psychopharmaceuticals", CHEMRXIV, 25 February 2025 (2025-02-25), XP093346428, Retrieved from the Internet <URL:https://chemrxiv.org/engage/chemrxiv/article-details/67be40466dde43c9087f7c4b> DOI: 10.26434/chemrxiv-2025-pjfn9 *
PANG XIN-HUI, YANG YANG, BIAN XIN, WANG BING, REN LI-KUN, LIU LIN-LIN, YU DE-HUI, YANG JING, GUO JING-CHUN, WANG LEI, ZHANG XIU-MI: "Hemp (Cannabis sativa L.) Seed Protein–EGCG Conjugates: Covalent Bonding and Functional Research", FOODS, MDPI AG, CH, vol. 10, no. 7, CH , pages 1618, XP093346425, ISSN: 2304-8158, DOI: 10.3390/foods10071618 *

Similar Documents

Publication Publication Date Title
US10898463B2 (en) High-strength oral cannabinoid dosage forms
US11931321B2 (en) Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same
EP2709607B1 (fr) Composition hydrosoluble comprenant de la curcumine ayant une plus grande biodisponibilité et procédé associé
KR20220016147A (ko) 카나비노이드 제형
RU2532384C2 (ru) Фармацевтическая композиция, проявляющая противовоспалительные свойства
JP7066627B2 (ja) タンニン酸を含有する組成物及びその使用
WO2021257586A1 (fr) Compositions pour compléter des produits avec des agents thérapeutiques et leurs procédés d&#39;utilisation
JP2021008509A (ja) トコトリエノールの経粘膜送達
US20240374519A1 (en) Compositions for supplementing products with therapeutic agents and methods of use thereof
US20220339227A1 (en) Compositions of cannabinoids for delivery by inhalation
IL292404A (en) Compositions including thin compounds and their production
US12419834B2 (en) Pomegranate oil for preventing and treating neurodegenerative diseases
US20240226005A1 (en) Nano- and micro-formulations
WO2023067509A1 (fr) Compositions pour complémenter des produits de kombucha avec des agents thérapeutiques et leurs procédés de fabrication et d&#39;utilisation
WO2025169152A1 (fr) Conjugués protéine végétale-polyphénol de thé vert utilisés comme émulsifiants
US20220193008A1 (en) Bioaccessibile compositions of lipophilic compounds and process thereof
CA3152428A1 (fr) Produit cannabinoide pour ameliorer la sante musculo-squelettique
US20070298136A1 (en) Cholesterol regulating agent
CN109195614A (zh) 用于治疗和预防神经疾病、神经炎症和阿尔茨海默病的组合物
WO2019145773A1 (fr) Formulations encapsulées dans des liposomes
IL308880A (en) Methods for the treatment of post-traumatic stress disorder and traumatic brain injury with cannabinoids
WO2022027053A1 (fr) Préparations de micelles d&#39;huile de chanvre à spectre complet pour le traitement du diabète de type ii, la réduction de l&#39;inflammation pendant le covid-19 et l&#39;amélioration de la qualité du sommeil
US12011470B2 (en) Micelle preparations of full-spectrum hemp oil
Das 16 Recent Advancement
Ayyagari et al. Evaluation of curcumin-loaded nanoliposomes for the treatment and prevention of age-related macular degeneration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25751820

Country of ref document: EP

Kind code of ref document: A1